RxDoctor Payments Data

Dennis Giang

Optometrist · Las Vegas, NVNPI 1710549480

Payments from drug & device makers

$1,365in general payments, 2019–2025

Across 39 payments — averaging $35.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$280
  • Johnson & Johnson Surgical Vision, Inc.$266
  • Alcon$180
  • Rxsight Inc$137
  • Aerie Pharmaceuticals, Inc.$120
  • Amgen$73
  • plus $311 from 8 others

What the payments were for

  • Food & beverage$1,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,365 in reported general payments places this provider in the 60th percentile of 494 optometrist providers in Nevada.

See all optometrist providers in Nevada

Medicare billing

Part B allowed, 2024
$167,745
Medicare patients
378
Services billed
1,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine81$100,696
XiidraLifitegrast31$31,124
LumiganBimatoprost17$7,994
Cyclosporine20$7,839
RocklatanNetarsudil Mesylat/Latanoprost11$3,435
ErythromycinErythromycin Base205$2,427
Fluorometholone13$1,531
Prednisolone Acetate39$1,299
Latanoprost130$1,279
Ofloxacin73$1,149
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat53$1,062
Timolol Maleate49$502
Brimonidine Tartrate17$355
MoxifloxacinMoxifloxacin Hcl12$353
Ketorolac Tromethamine11$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$280$108,69098 claims
Bausch & Lomb Americas Inc.Xiidra$24$31,12431 claims
Aerie Pharmaceuticals, Inc.Rocklatan$120$3,43511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 494 optometrist providers in Nevada.

Other optometrist in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →